

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on April 16, 2004

Paula F Dutt
Name of Person Mailing

Signsture of Person Mailing

P&G Case 9438Q

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Tim Jensen : Confirmation No. 2947 Serial No. 10/719,799 : Group Art Unit 3762

Filed November 21, 2003 : Examiner

For Tampon Having Recessed Portions

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

# 2. [X] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

# ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the						
cited documents are enclosed.						
OR						
[X] (2) (For use with applications filed after June 30, 2003.) In accordance with						
37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.						
OR						
[] (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.						
OR						
(4) Copies of all said documents, except Cite Numbers, were submitted and considered in parent application U.S. Patent Application Serial No, filed Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.						
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.						
[] (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.						
[] Additional information is attached.						
Respectfully submitted,						
Date: April 16, 2004  Customer No. 27752  (IDS.doc) (Last Revised 10/10/03)  By Ingrid N. Hickman  Attorney or Agent for Applicant(s)  Registration No. 46,770  (513)634-5395						

# **CO-PENDING U.S. APPLICATIONS**

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) <u>must</u> be sent with the IDS (see 37 CFR 1.98(a)(2)(iii)

Atty. Docket No.	Serial Number	Inventor(s)	Filing Date
9431	10/719,786	Carlin	11/21/03
9432	10/719,785	Carlin	11/21/03
9433	10/719,258	Carlin	11/21/03
9434	10/719,793	Carlin	11/21/03
9435	10/719,263	Carlin	11/21/03
9436P	60/524,225	Osborn	11/21/03
9437Q	10/719,259	Carlin	11/21/03
9439Q	10/719,747	Jensen	11/21/03
9440Q	10/719,600	Jensen	11/21/03

[Only applications that remain pending at the time of submitting this IDS should be listed here. For applications in which patents have issued, the granted patents should be listed on Form PTO/SB08.]

Under the Paperwork Reduction Act of 1995, no

Substitute for form 1449ACTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

	ETE IE WYONE				
COMPLETE IF KNOWN					
Application Number	10/719,799				
Confirmation Number	2947				
Filing Date	November 21, 2003				
First Named Inventor	Tim Jensen				
Group Art Unit	3762				
Examiner Name					
Attorney Docket Number	9438Q				

### **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	<u> </u>	US-2,123,750	07-12-1938	Schulz	Figures Appear
		US-3,738,364	06-12-1973	Brien, et al	
	<u> </u>	US-3,854,481	12-17-1974	Messing	
	<u> </u>	US-3,946,737	03-30-1976	Kobler	
		US-4,326,527	04-27-1982	Wollangk, et al.	
		US-4,591,523	05-27-1986	Thompson	
	L	US-4,609,518	09-02-1986	Curro, et al.	<del></del>
		US-4,629,643	12-16-1986	Curro, et al.	
		US-4,685,178	08-11-1987	Nakanishi	
		US-4,839,216	06-13-1989	Curro, et al.	
		US-4,951,368	08-28-1990	Heinen	
<u></u>		US-5,153,971	10-13-1992	Van Iten	
		US-5,350,371	09-27-1994	Van Iten	
		US-5,592,725	01-14-1997	Brinker	
		US-5,788,910	08-04-1998	McNeilis, et al.	
		US-5,832,576	11-10-1998	Leutwyler, et al.	
		US-5,891,081	04-06-1999	McNelis, et al.	
		US-5,911,712	06-15-1999	Leutwyler, et al.	
		US-5,958,321	09-28-1999		
		US-6,003,216	12-21-1999	Schoelling, et al.	
		US-6,071,259	06-06-2000	Hull, Jr., et al.	
		US-6,156,021	12-05-2000	Steiger, et al.	
		US-6,283,952 B1	09-04-2001	Tojkander	
	$\overline{}$	US-6,310,269 B1	10-30-2001	Child, et al.	
		US-2002/0151859 A1	10-17-2002	Friese, et al.	
		20 20 20 10 10 03 A1	1 10-17-2002	Schoelling	

#### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DOCUMENT  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
		EP 0 422 660 B1	02-09-1994	Friese	- дреш	<del></del>
		WO 00/37013 A1	06-29-2000	Zunker		
		WO 01/66055 A1	09-13-2001	Paulev	<del></del>	
		WO 02/078586 A3	10-10-2002	Schoelling		<del></del>
EXAMINER	INER			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'See Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)